PE20241327A1 - Tratamiento de trastornos hepaticos con un agonista del thr-beta - Google Patents
Tratamiento de trastornos hepaticos con un agonista del thr-betaInfo
- Publication number
- PE20241327A1 PE20241327A1 PE2024001030A PE2024001030A PE20241327A1 PE 20241327 A1 PE20241327 A1 PE 20241327A1 PE 2024001030 A PE2024001030 A PE 2024001030A PE 2024001030 A PE2024001030 A PE 2024001030A PE 20241327 A1 PE20241327 A1 PE 20241327A1
- Authority
- PE
- Peru
- Prior art keywords
- thr
- treatment
- liver disorders
- beta agonist
- patient
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Oil, Petroleum & Natural Gas (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2021130083 | 2021-11-11 | ||
| CN2022097426 | 2022-06-07 | ||
| PCT/CN2022/131297 WO2023083288A1 (en) | 2021-11-11 | 2022-11-11 | TREATMENT OF LIVER DISORDERS WITH A THR-β AGONIST |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20241327A1 true PE20241327A1 (es) | 2024-06-26 |
Family
ID=86335128
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2024001030A PE20241327A1 (es) | 2021-11-11 | 2022-11-11 | Tratamiento de trastornos hepaticos con un agonista del thr-beta |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20240293416A1 (https=) |
| EP (1) | EP4429666A4 (https=) |
| JP (1) | JP2024544538A (https=) |
| KR (1) | KR20240101642A (https=) |
| CN (1) | CN118871113A (https=) |
| AU (1) | AU2022388507A1 (https=) |
| CA (1) | CA3238108A1 (https=) |
| CL (1) | CL2024001399A1 (https=) |
| CO (1) | CO2024007225A2 (https=) |
| IL (1) | IL312637A (https=) |
| MX (1) | MX2024005647A (https=) |
| PE (1) | PE20241327A1 (https=) |
| TW (1) | TW202332447A (https=) |
| WO (1) | WO2023083288A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111320609A (zh) | 2018-12-13 | 2020-06-23 | 拓臻股份有限公司 | 一种THRβ受体激动剂化合物及其制备方法和用途 |
| AU2020336272A1 (en) | 2019-08-23 | 2022-04-14 | Terns Pharmaceuticals, Inc. | Thyroid hormone receptor beta agonist compounds |
| WO2021050945A1 (en) | 2019-09-12 | 2021-03-18 | Terns, Inc. | Thyroid hormone receptor beta agonist compounds |
| EP4568664B1 (en) | 2023-04-07 | 2026-04-01 | Terns Pharmaceuticals, Inc. | Combination comprising a thr-beta agonist and a glp-1r agonist for use in treating obesity |
| WO2025245216A1 (en) * | 2024-05-22 | 2025-11-27 | Terns Pharmaceuticals, Inc. | Treatment of liver disorders with a thr-beta agonist |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018075650A1 (en) * | 2016-10-18 | 2018-04-26 | Madrigal Pharmaceuticals, Inc. | Methods of treating liver disorders or lipid disorders with a thr-beta agonist |
| AR115666A1 (es) * | 2018-07-02 | 2021-02-10 | Madrigal Pharmaceuticals Inc | Formas sólidas de 2-(3,5-dicloro-4-((5-isopropil-6-oxo-1,6-dihidropiridazin-3-il)oxi)fenil)-3,5-dioxo-2,3,4,5-tetrahidro-1,2,4-triazin-6-carbonitrilo |
| CN111320609A (zh) * | 2018-12-13 | 2020-06-23 | 拓臻股份有限公司 | 一种THRβ受体激动剂化合物及其制备方法和用途 |
| WO2020228577A1 (zh) * | 2019-05-10 | 2020-11-19 | 深圳微芯生物科技股份有限公司 | 一种哒嗪酮衍生物及其应用 |
| TW202128668A (zh) * | 2019-12-16 | 2021-08-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | 并環類衍生物、其製備方法及其在醫藥上的應用 |
| US20210379043A1 (en) * | 2020-05-13 | 2021-12-09 | Terns Pharmaceuticals, Inc. | Combination treatment of liver disorders |
| CN114437034A (zh) * | 2020-11-06 | 2022-05-06 | 深圳微芯生物科技股份有限公司 | 一种酞嗪类化合物的可药用盐、晶型及其制备方法 |
-
2022
- 2022-11-11 PE PE2024001030A patent/PE20241327A1/es unknown
- 2022-11-11 AU AU2022388507A patent/AU2022388507A1/en active Pending
- 2022-11-11 CA CA3238108A patent/CA3238108A1/en active Pending
- 2022-11-11 KR KR1020247018844A patent/KR20240101642A/ko active Pending
- 2022-11-11 WO PCT/CN2022/131297 patent/WO2023083288A1/en not_active Ceased
- 2022-11-11 EP EP22892081.5A patent/EP4429666A4/en active Pending
- 2022-11-11 MX MX2024005647A patent/MX2024005647A/es unknown
- 2022-11-11 TW TW111143222A patent/TW202332447A/zh unknown
- 2022-11-11 CN CN202280087379.7A patent/CN118871113A/zh active Pending
- 2022-11-11 IL IL312637A patent/IL312637A/en unknown
- 2022-11-11 JP JP2024527603A patent/JP2024544538A/ja active Pending
-
2024
- 2024-05-01 US US18/651,843 patent/US20240293416A1/en active Pending
- 2024-05-09 CL CL2024001399A patent/CL2024001399A1/es unknown
- 2024-06-07 CO CONC2024/0007225A patent/CO2024007225A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| TW202332447A (zh) | 2023-08-16 |
| WO2023083288A1 (en) | 2023-05-19 |
| KR20240101642A (ko) | 2024-07-02 |
| CN118871113A (zh) | 2024-10-29 |
| CL2024001399A1 (es) | 2024-11-08 |
| EP4429666A1 (en) | 2024-09-18 |
| CA3238108A1 (en) | 2023-05-19 |
| US20240293416A1 (en) | 2024-09-05 |
| CO2024007225A2 (es) | 2024-10-31 |
| AU2022388507A1 (en) | 2024-06-20 |
| EP4429666A4 (en) | 2025-12-24 |
| JP2024544538A (ja) | 2024-12-03 |
| IL312637A (en) | 2024-07-01 |
| MX2024005647A (es) | 2024-05-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20241327A1 (es) | Tratamiento de trastornos hepaticos con un agonista del thr-beta | |
| UY35624A (es) | Uso de dosis elevadas de pridopidina para tratar la enfermedad de huntington | |
| LU92642I2 (fr) | Pomalidomide et ses sels, solvates, hydrates ou stéréoisomères pharmaceutiquement acceptables qui endérivent (Imnovid) | |
| AR119158A1 (es) | Tratamientos de angioedema hereditario | |
| NI201100147A (es) | Métodos para tratar infartos agudos de miocardio y trastornos relacionados. | |
| CO6220969A2 (es) | Adminsitracion semanal de inhibidores de peptidasa de dipeptidilo | |
| CU23468B7 (es) | Forma de dosificación de pramipexol en una dosis única diaria | |
| AR070047A1 (es) | Tratamientos terapeuticos contra el cancer. composicion que comprende un inhibidor de hedgehog. | |
| AR082803A1 (es) | Metodos y formulaciones para el tratamiento de la trombosis con betrixaban y un inhibidor de la glicoproteina p | |
| AR090885A1 (es) | Uso de laquinimod en alta dosis para el tratamiento de la esclerosis multiple | |
| ECSP10010052A (es) | Formulaciones galenicas de alisquireno y valsartan | |
| MX2023012875A (es) | Inhibidores 2-fluoro alquil-l,3,4-oxadiazol-5-il-tiazol de hdac6 para su uso en el tratamiento de enfermedades metabólicas y hfpef. | |
| ZA202000028B (en) | Use of vibegron to treat overactive bladder | |
| AR119159A1 (es) | Tratamientos de angioedema | |
| CL2024003601A1 (es) | Nuevas combinaciones terapéuticas para el tratamiento de enfermedades pulmonares intersticiales fibrosantes progresivas. | |
| AR046036A1 (es) | Composiciones de risedronato y metodos para su uso | |
| MX2022016406A (es) | Metodos para tratar el cancer o enfermedad de von-hippel lindau usando una combinacion de un inhibidor de hif-2 alpha y lenvatinib. | |
| AR114306A1 (es) | Tratamiento y prevención de trastornos del sueño | |
| MX2019001412A (es) | Compuestos de 9-aminometil minociclina y usos de los mismos. | |
| AR029666A1 (es) | Uso del (+) -alfa-(2,3-dimetoxifenil)-1-[2-(4-fluorofenil)etil]-4-piperidinmetanol o su prodroga para la manufactura de un medicamento en el tratamiento de los sintomas de la demencia y de la psicosis inducida por dopamina | |
| WO2021262562A3 (en) | Methods for treating cancer or von-hippel lindau disease using a combination of a pd-1 antagonist, a hif-2 alpha inhibitor, and lenvatinib or a pharmaceutically acceptable salt thereof | |
| MX2022016410A (es) | Metodos para tratar el cancer o enfermedad de von-hippel lindau usando una combinacion de un antagonista del pd-1, inhibidor de hif-2 alpha y lenvatinib o una sal aceptable farmeuticamente de estos. | |
| PE20040706A1 (es) | Derivado especifico de amina ciclica y sus sales farmaceuticamente aceptables involucrados en la prevencion de la insuficiencia cardiaca | |
| AR131842A1 (es) | Métodos para tratar gliomas | |
| MX2023013514A (es) | Metodos para tratar la cistitis intersticial/sindrome de dolor en la vejiga. |